243 related articles for article (PubMed ID: 30078176)
21. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
23. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
[TBL] [Abstract][Full Text] [Related]
24. Treatment persistence of biologics among patients with psoriatic arthritis.
Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
[TBL] [Abstract][Full Text] [Related]
25. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
26. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review.
Khan S; Rupniewska E; Neighbors M; Singer D; Chiarappa J; Obando C
J Clin Pharm Ther; 2019 Aug; 44(4):495-507. PubMed ID: 30873648
[TBL] [Abstract][Full Text] [Related]
27. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
[TBL] [Abstract][Full Text] [Related]
28. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.
Morgan C; McBeth J; Cordingley L; Watson K; Hyrich KL; Symmons DP; Bruce IN
Rheumatology (Oxford); 2015 Oct; 54(10):1780-91. PubMed ID: 25972390
[TBL] [Abstract][Full Text] [Related]
29. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
30. Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study.
Michetti P; Weinman J; Mrowietz U; Smolen J; Peyrin-Biroulet L; Louis E; Schremmer D; Tundia N; Nurwakagari P; Selenko-Gebauer N
Adv Ther; 2017 Jan; 34(1):91-108. PubMed ID: 27854054
[TBL] [Abstract][Full Text] [Related]
31. Biologic efficacy optimization--a step towards personalized medicine.
Kiely PD
Rheumatology (Oxford); 2016 May; 55(5):780-8. PubMed ID: 26424837
[TBL] [Abstract][Full Text] [Related]
32. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy.
Chen C; Hartzema AG; Xiao H; Wei YJ; Chaudhry N; Ewelukwa O; Glover SC; Zimmermann EM
Inflamm Bowel Dis; 2019 Jul; 25(8):1417-1427. PubMed ID: 30839057
[TBL] [Abstract][Full Text] [Related]
33. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
Ballegaard C; Højgaard P; Dreyer L; Cordtz R; Jørgensen TS; Skougaard M; Tarp S; Kristensen LE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):592-599. PubMed ID: 28772007
[TBL] [Abstract][Full Text] [Related]
34. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
35. Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations.
da Silva MRR; Dos Santos JBR; Almeida AM; Guerra Júnior AA; Alvares Teodoro J; Acurcio FA
Expert Rev Clin Immunol; 2019 Aug; 15(8):879-887. PubMed ID: 31192746
[No Abstract] [Full Text] [Related]
36. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
37. Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset.
Youssef P; Marcal B; Button P; Truman M; Bird P; Griffiths H; Roberts L; Tymms K; Littlejohn G
J Rheumatol; 2020 Aug; 47(8):1174-1181. PubMed ID: 31787605
[TBL] [Abstract][Full Text] [Related]
38. A review of neurologic complications of biologic therapy in plaque psoriasis.
Lin EJ; Reddy S; Shah VV; Wu JJ
Cutis; 2018 Jan; 101(1):57-60. PubMed ID: 29529105
[TBL] [Abstract][Full Text] [Related]
39. Adherence to Anti-Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis.
Salaffi F; Carotti M; Di Carlo M; Farah S; Gutierrez M
J Clin Rheumatol; 2015 Dec; 21(8):419-25. PubMed ID: 26587852
[TBL] [Abstract][Full Text] [Related]
40. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
